Screener
Halozyme Therapeutics HALO Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.
The source filing: Halozyme Therapeutics’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:11 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001159036-26-000104
FAQ
- What is Halozyme Therapeutics's accounts payable?
- Halozyme Therapeutics (HALO) reported accounts payable of $23.61M in Q2 2026.
- How has Halozyme Therapeutics's accounts payable changed year-over-year?
- Halozyme Therapeutics's accounts payable increased by 26.3% year-over-year, from $18.69M to $23.61M.
- What is the long-term trend for Halozyme Therapeutics's accounts payable?
- Over 5 years (2020 to 2025), Halozyme Therapeutics's accounts payable has grown at a 61.1% compound annual growth rate (CAGR), from $1.93M to $20.9M.
- What does accounts payable mean?
- Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.
Ask your AI about Halozyme Therapeutics's accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude